WEST PHARMACEUTICAL SERVICES, INC. (WST) FY2026 Q2 Balance Sheet

WEST PHARMACEUTICAL SERVICES, INC. (WST) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets

4,076,400,000 US dollars

Current assets

1,807,500,000 US dollars

Non-current assets

2,268,900,000 US dollars

Liabilities

1,086,200,000 US dollars

Current liabilities

640,500,000 US dollars

Non-current liabilities

445,700,000 US dollars

Equity

2,990,200,000 US dollars

Property, plant and equipment

3,248,600,000 US dollars. Part of Property, plant and equipment, net, drawn as one net amount.

Less: accumulated depreciation and amortization

negative 1,562,300,000 US dollars. Part of Property, plant and equipment, net, drawn as one net amount.

Accounts receivable, net

712,000,000 US dollars

Inventories

447,400,000 US dollars

Cash and cash equivalents

435,800,000 US dollars

Other current assets

212,300,000 US dollars

Property, plant and equipment, net

1,686,300,000 US dollars

Investments in affiliated companies

207,700,000 US dollars

Goodwill

108,700,000 US dollars

Operating lease right-of-use assets

104,700,000 US dollars

Other noncurrent assets

82,800,000 US dollars

Deferred income taxes

72,300,000 US dollars

Intangible assets, net

6,400,000 US dollars

Accounts payable

252,700,000 US dollars

Other current liabilities

171,100,000 US dollars

Accrued salaries, wages and benefits

97,100,000 US dollars

Income taxes payable

64,700,000 US dollars

Accrued commissions, rebates and royalties

34,000,000 US dollars

Operating lease liabilities

20,900,000 US dollars

Long-term debt

202,900,000 US dollars

Other long-term liabilities

89,900,000 US dollars

Operating lease liabilities

88,300,000 US dollars

Pension and other postretirement benefits

28,300,000 US dollars

Deferred income taxes

22,400,000 US dollars

Deferred compensation benefits

13,900,000 US dollars

Retained earnings

4,624,100,000 US dollars

Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: June 30, 2026 - 75.3 million, December 31, 2025 - 75.3 million; shares outstanding: June 30, 2026 - 70.4 million, December 31, 2025 - 72.0 million

18,800,000 US dollars

Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding

0 US dollars

Capital in excess of par value

0 US dollars

Treasury stock, at cost (June 30, 2026 - 4.9 million shares, December 31, 2025 - 3.3 million shares)

negative 1,512,300,000 US dollars

Accumulated other comprehensive loss

negative 140,400,000 US dollars

Gross equity (calculated)

4,642,900,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

• Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.